Add this topic to your myFT Digest for news straight to your inbox
With a bidding war for Allergan, who the buyer is matters less than the size of the premium
Portfolio of generic drugs snapped up
If you trust the strategy, buy shares
Deal is latest sign of merger activity among pharmaceuticals
The $8.5bn deal lacks flash, but the price is right
International Edition